Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OB0F
|
|||
| Former ID |
DCL000369
|
|||
| Drug Name |
Bosutinib
|
|||
| Synonyms |
SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Wyeth Research
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H29Cl2N5O3
|
|||
| Canonical SMILES |
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
|
|||
| InChI |
1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
|
|||
| InChIKey |
UBPYILGKFZZVDX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 380843-75-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8034215, 11061176, 14720373, 14885411, 17397405, 26676000, 26746630, 39301565, 53641516, 56459346, 57361290, 85246176, 92721109, 103220856, 113911152, 118844931, 124950167, 125011711, 125349351, 126627733, 126647930, 126666992, 126731247, 134339019, 134964339, 135246638, 135642791, 135684978, 135685144, 135685145, 135685164, 135697655, 136340225, 136368026, 136920303, 137127131, 139943916, 143495997, 144115749, 152041940, 152234943, 152258097, 152344342, 160646936, 162011701, 162170730, 162201602, 162256836, 163884826, 164041898
|
|||
| ChEBI ID |
CHEBI:39112
|
|||
| ADReCS Drug ID | BADD_D00286 ; BADD_D00287 | |||
| SuperDrug ATC ID |
L01XE14
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5710). | |||
| REF 2 | ClinicalTrials.gov (NCT02311998) Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML). U.S. National Institutes of Health. | |||
| REF 3 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.